Recently diagnosed with HIV? Click here

Tipranavir

aprivus.jpg

Tipranavir is one of a new class of HIV protease inhibitorsA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate. called dihydropyrones or non-peptidic protease inhibitors. It is designed to be active against HIV strains that have become resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. to other protease inhibitors. For this reason it is most useful in salvage[salvage therapy] A treatment strategy for managing HIV in people who have developed resistance to existing therapies. or multiple-treatment experienced regimens.

Generic name: tipranavir (TPV)
Pronunciation:ti-PRAN-aveer
Brand name:Aptivus
Drug class:protease inhibitor
Pediatric dosing?Available in doses suitable for children and/or young people.
Availability in Australia:
  • Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers.
  • This drug may be available through clinical trials in Australia.
  • You may be able to import this drug from overseas for your personal use.
Presentation:250mg capsule
Links:

Like most anti-HIV drugs, tipranavir must be taken in combination with other drugs to be completely effective. Commonly, tipranavir is combined with two nucleoside (NRTI) drugs, although other combinations are sometimes used. Your doctor will advise you on the right combination of drugs to suit your circumstances.

Dosage

2 x 250mg capsules + 200mg ritonavir twice daily

Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.

With or without food?

Tipranavir should be taken with food.

Side effects

All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.

  • Common side effects may include nausea (upset stomach, feeling sick to the stomach), diarrhoea, vomiting, headache, fatigue, stomach pain.
  • Less common side effects may include rash or sensitivity to the sun, joint pain or stiffness, itching, tightness in the throat..
  • Rare side effects may include hepatitis, increases in cholesterol and triglycerides (blood fats), liver failure.

    • It's unlikely you will experience all of these side effects, and you may not experience any side effects at all. Before starting any new drug, ask your doctor about side effects you might experience and discuss strategies for dealing with side effects if they do occur. If you experience any significant side effect you should continue taking your medicine and see your doctor as soon as possible.

Interactions with other drugs

Drugs to watch out for include other ARVs, drugs to treat tuberculosis, for erectile dysfunction (such as Viagra), for heart rhythm (antiarrhythmics), and for migraine headaches. Interactions are also possible with several antihistamines (allergy medications), sedatives, drugs to lower cholesterol, and anti-fungal drugs. Tipranavir raises blood levels of midazolam, a sedative. They should not be taken together without careful monitoring. Some birth control pills may not work if you are taking Tipranavir. Tipranavir lowers blood levels of methadone. Watch for signs of excessive sedation if you take tipranavir with buprenorphine. The herb St. John's Wort lowers the blood levels of some protease inhibitors. Do not take it while taking tipranavir.
AttachmentSizeType
CMR06755.pdf30.1 KBCMR06755.pdfPDF

ASHM 2006: Strategies for coping with multiple drug resistance

Positive Living article • Paul Kidd • 21 December 2006

Finding effective treatment options for people who have taken many treatments and have multiple resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant.. mutations continues to be a significant challenge for HIV clinicians, and their patients. read more »

News and Treatments Briefs

Positive Living article • Paul Kidd • 21 December 2006
Positive women

HIV-related news in brief from the December 2006 edition of Positive Living. read more »

Warning on tipranavir

Positive Living article • Paul Kidd • 10 July 2006

Access to the new protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate. tipranavir (Aptivus) has been substantially expanded in Australia, but there are new questions about the drug’s effectiveness(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase IIA smaller clinical trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase III study is undertaken, with a larger number of participaants, to confirm this. clinical trials gauge efficacy, and Phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. trials confirm it. and warnings about serious side effects. read more »

Much more than a junket

Positive Living article • Paul Kidd • 13 October 2005

A report from the 3rd IAS Conference on HIV Pathogenesis and Treatment, held in Rio de Janiero in July. read more »

Rescue me

Positive Living article • Paul Kidd • 19 May 2005

What are the options when you’re running out of options? read more »

Breaking the drought

Positive Living article • Kirsty Machon • 24 March 2005

It's been a while since there was much cause for excitement in the drug pipeline, and even now there's just one anti-HIV drug nearing the end of the development maze. But, says KIRSTY MACHON, a new generation of HIV treatments promises to break the drought. read more »

A tale of two cities

Positive Living article • Paul Kidd • 19 December 2004

With major medical conferences in the United States and Scotland, November was a busy month for HIV medicine. PAUL KIDD reviews some key findings. read more »

'The greatest health crisis in human history'

Positive Living article • Paul Kidd • 1 August 2003

The major international AIDS conference for 2003 has ended with encouraging signs of growing international commitment to fight AIDS in the developing world, and with several promising medical developments. read more »

The table below shows all the clinical trials in the database with the keyword tipranavir.

Sorry, no clinical trials database entries were found that matched your request.

Syndicate content
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Treatments database entry was first published on 3 June 2009 — more than two years ago.

While the content of this treatments database entry was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more